Phototheranostics: Active Targeting of Orthotopic Glioma Using Biomimetic Proteolipid Nanoparticles

Transcription

1 Supporting information Phototheranostics: Active Targeting of Orthotopic Glioma Using Biomimetic Proteolipid Nanoparticles Yali Jia,,, Xiaobing Wang,, Dehong Hu, Pan Wang, Quanhong Liu, Xuanjun Zhang, # Jingying Jiang, Xin Liu, Zonghai Sheng,,* Bin Liu,,* and Hairong Zheng,* Paul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen , China. Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi an , China. Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore , Singapore. # Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China. 1

2 Contents Table S1...3 Figures S1...4 Figures S2...5 Figures S3...6 Figures S4...7 Figures S5...8 Figures S6...9 Figures S Figures S Figures S Figures S Figures S Figures S Figures S Figures S

3 Figures S Figures S Figures S References...21 Table S1. Currently explored cancer cells for biomimetic NPs. 3

4 4

5 Figure S1 Zeta potentials in LIPO-ICG, BLIPO-ICG and CMP. 5

6 Figure S2 (a) The concentration of BLIPO-ICG detected by qnano analyzer. (b) The protein standard curve of bovine serum albumin (BSA) detected by BCA method. The concentrations of BSA ranged from to 2000 μg/ml. 6

7 Figure S3 The respective diameters of BLIPO-ICG in (a) H 2 O, (b) PBS and (c) 10% FBS. 7

8 Figure S4 The respective fluorescence spectra of (a) free ICG and (b) BLIPO-ICG in 10% FBS. 8

9 Figure S5 Flow cytometric profile of C6 cells after 2 h incubation with LIPO-ICG and BLIPO-ICG. 9

10 Figure S6 Flow cytometric profile of RAW264.7 cells after 2 h incubation with LIPO-ICG and BLIPO-ICG. 10

11 Figure S7 Viability of C6 cells against BLIPO-ICG NPs at different concentrations after 24 h incubation. 11

12 Figure S8 Viability of bend.3 endothelial cells against BLIPO-ICG NPs at different concentrations after 24 h incubation. 12

13 Figure S9 Semi-quantitative analysis of ROI from tumor and normal tissues in subcutaneous C6 tumor-bearing mice at 12 h post injection. The S/B ratio was calculated using the following equation: S/B=ROI (tumor) /Averaged ROI (1-5). 13

14 Figure S10 Semi-quantitative analysis of ROI from tumor and normal tissues in orthotopic C6 tumor-bearing mice at 12 h post injection. The S/B ratio was calculated using the following equation: S/B=ROI (tumor) /Averaged ROI (1-5). 14

15 Figure S11 Semi-quantitative analysis of ROI from tumor and normal tissues in tiny orthotopic C6 tumor-bearing mice at 12 h post injection. The S/B ratio was calculated using the following equation: S/B=ROI (tumor) /Averaged ROI (1-5). 15

16 16

17 Figure S12 Semi-quantitative analysis of ROI from tumor and normal tissues at 12 h post injection. The S/B ratio was calculated using the following equation: S/B=ROI (tumor) /Averaged ROI (1-5). 17

18 Figure S13 Local temperature-increase profiles of laser-irradiated tumor after injection of LIPO-ICG and BLIPO-ICG in subcutaneous C6 tumor-bearing mice. 18

19 Figure S14 H&E stained results of adjacent normal tissues, which were collected from mice treated with PTT. 19

20 Figure S15 Representative photographs of subcutaneous C6 tumor-bearing mice during the treatment and photographs of tumor tissues at the end of the treatment. 20

21 Figure S16 H&E staining of major organs from subcutaneous C6 tumor-bearing mice after different treatment. 21

22 Figure S17 Local temperature-increase profiles of laser-irradiated glioma after injection of LIPO-ICG and BLIPO-ICG in orthotopic C6 tumor-bearing mice. 22

23 References 1. Rao, L.; Bu, L.; Cai, B.; Xu, J.; Li, A.; Zhang, W.; Sun, Z.; Guo, S.; Liu, W.; Wang, T.; Zhao, X. Cancer Cell Membrane-Coated Upconversion Nanoprobes for Highly Specific Tumor Imaging. Adv Mater. 2016, 28, Chen, Z.; Zhao, P.; Luo, Z.; Zheng, M.; Tian, H.; Gong, P.; Gao, G.; Pan, H.; Liu, L.; Ma, A.; Cui, H.; Ma, Y.; Cai, L. Cancer Cell Membrane-Biomimetic Nanoparticles for Homologous-Targeting Dual-Modal Imaging and Photothermal Therapy. ACS Nano 23

24 2016, 10, Li, S. Y.; Cheng, H.; Xie, B. R.; Qiu, W. X.; Zeng, J. Y.; Li, C. X.; Wan, S. S.; Zhang, L.; Liu, W.; Zhang, X. Cancer Cell Membrane Camouflaged Cascade Bioreactor for Cancer Targeted Starvation and Photodynamic Therapy. ACS Nano 2017, 11, Lv, Y.; Liu, M.; Zhang, Y.; Wang, X.; Zhang, F.; Li, F.; Bao, W. E.; Wang, J.; Zhang, Y.; Wei, W.; Ma, G.; Zhao, L.; Tian, Z. Cancer Cell Membrane-Biomimetic Nanoprobes with Two-Photon Excitation and Near-Infrared Emission for Intravital Tumor Fluorescence Imaging. ACS Nano 2018, 12, Balasubramanian, V.; Correia, A.; Zhang, H.; Fontana, F.; Makila, E.; Salonen, J.; Hirvonen, J.; Santos, H. A. Biomimetic Engineering Using Cancer Cell Membranes for Designing Compartmentalized Nanoreactors with Organelle-Like Functions. Adv Mater. 2017, 29, Fontana, F.; Shahbazi, M. A.; Liu, D.; Zhang, H.; Makila, E.; Salonen, J.; Hirvonen, J. T.; Santos, H. A. Multistaged Nanovaccines Based on Porous Cell Membrane for Cancer Immunotherapy. Adv Mater. 2017, 29, Yu, B.; Goel, S.; Ni, D.; Ellison, P. A.; Siamof, C. M.; Jiang, D.; Cheng, L.; Kang, 24

25 L.; Yu, F.; Liu, Z.; Barnhart, T. E.; He, Q.; Zhang, H.; Cai, W. Reassembly of (89) Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics. Adv Mater. 2018, Sun, H.; Su, J.; Meng, Q.; Chen, L.; Gu, W.; Zhang, Z.; Yu, H.; Zhang, P.; Wang, S.; Li, Y. Cancer Cell Membrane-Coated Gold Nanocages with Hyperthermia-Triggered Drug Release and Homotypic Target Inhibit Growth and Metastasis of Breast Cancer. Adv. Funct. Mater. 2017, Noh, Y.; Kim, S.; Kim, J., Kim, S.; Ryu, J.; Kim, I.; Lee, E.; Um, S.; Lim, Y. Multifaceted Immunomodulatory Nanoliposomes: Reshaping Tumors into Vaccines for Enhanced Cancer Immunotherapy. Adv. Funct. Mater. 2017, Cheng, H.; Zhu, J. Y.; Li, S. Y.; Zeng, J. Y.; Lei, Q.; Chen, K. W.; Zhang, C.; Zhang, X. Z. An O 2 Self-Sufficient Biomimetic Nanoplatform for Highly Specific and Efficient Photodynamic Therapy. Adv. Funct. Mater. 2016, 26, Tian, H.; Luo, Z.; Liu, L.; Zheng, M.; Chen, Z.; Ma, A.; Liang, R.; Han, Z.; Lu, C.; Cai, L. Cancer Cell Membrane-Biomimetic Oxygen Nanocarrier for Breaking Hypoxia-Induced Chemoresistance. Adv. Funct. Mater. 2017, 27, Kroll, A. V.; Fang, R. H.; Jiang, Y.; Zhou, J.; Wei, X.; Yu, C. L.; Gao, J.; Luk, B. 25

26 T.; Dehaini, D.; Gao, W.; Zhang, L. Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. Adv Mater. 2017, 29, Li, Y. J.; Yang, C. X.; Yan, X. P. Biomimetic Persistent Luminescent Nanoplatform for Autofluorescence-Free Metastasis Tracking and Chemophotodynamic Therapy. Anal. Chem. 2018, 90, Zhu, J.; Zhang, M.; Zheng, D.; Hong, S.; Feng, J.; Zhang, X. Z. A Universal Approach to Render Nanomedicine with Biological Identity Derived from Cell Membranes. Biomacromolecules 2018,19, Li, S. Y.; Xie, B. R.; Cheng, H.; Li, C. X.; Zhang, M. K.; Qiu, W. X.; Liu, W. L.; Wang, X. S.; Zhang, X. Z. A Biomimetic Theranostic O 2 -Meter for Cancer Targeted Photodynamic Therapy and Phosphorescence Imaging. Biomaterials 2018, 151, Li, S. Y.; Cheng, H.; Qiu, W. X.; Zhang, L.; Wan, S. S.; Zeng, J. Y.; Zhang, X. Z. Cancer Cell Membrane-Coated Biomimetic Platform for Tumor Targeted Photodynamic Therapy and Hypoxia-Amplified Bioreductive Therapy. Biomaterials 2017, 142, Qiu, W. X.; Zhang, M. K.; Liu, L. H.; Gao, F.; Zhang, L.; Li, S. Y.; Xie, B. R.; Zhang, C.; Feng, J.; Zhang, X. Z. A Self-Delivery Membrane System for Enhanced Anti-Tumor Therapy. Biomaterials 2018, 161, Zhang, N.; Li, M.; Sun, X.; Jia, H.; Liu, W. NIR-Respronsive Ccancer 26

27 Cytomembrane-Cloaked Carrier-Free Nanosystems for Highly Efficient and Self-Targeted Tumor Drug Delivery. Biomaterials 2018, 159, Li, J.; Wang, X.; Zheng, D.; Lin, X.; Wei, Z.; Zhang, D.; Li, Z.; Zhang, Y.; Wu, M.; Liu, X. Cancer Cell Membrane-Coated Magnetic Nanoparticles for MR/NIR Fluorescence Dual-Modal Imaging and Photodynamic Therapy. Biomater. Sci. 2018, 6, Fang, R. H.; Hu, C. M.; Luk, B. T.; Gao, W.; Copp, J. A.; Tai, Y.; O'Connor, D. E.; Zhang, L. Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vccination and Drug Delivery. Nano Lett. 2014, 14, Zhu, J. Y.; Zheng, D. W.; Zhang, M. K.; Yu, W. Y.; Qiu, W. X.; Hu, J. J.; Feng, J.; Zhang, X. Z. Preferential Cancer Cell Self-Recognition and Tumor Self-Targeting by Coating Nanoparticles with Homotypic Cancer Cell Membranes. Nano Lett. 2016, 16, Sun, H.; Su, J.; Meng, Q.; Yin, Q.; Chen, L.; Gu, W.; Zhang, P.; Zhang, Z.; Yu, H.; Wang, S.; Li, Y. Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors. Adv Mater. 2016, 28, Yang, R.; Xu, J.; Xu, L. G.; Sun, X. Q.; Chen, Q.; Zhao, Y. H.; Peng, R.; Liu, Z. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for 27

28 Effective Anticancer Vaccination. ACS Nano 2018, doi: /acsnano.7b Zou, M. Z.; Liu, W. L.; Li, C. X.; Zheng, D. W.; Zeng, J. Y.; Gao, F.; Ye, J. J.; Zhang, X. Z. A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis. Small 2018, 28, e Shao, D.; Li, M.; Wang, Z.; Zheng, X.; Lao, Y. H.; Chang, Z.; Zhang, F.; Lu, M.; Yue, J.; Hu, H.; Chen, L.; Dong, W. F., Leong, K. W. Bioinspired Diselenide-Bridged Mesoporous Silica Nanoparticles for Dual-Responsive Protein Delivery. Adv Mater. 2018, 28, e Xu, Q. B.; Wan, J. S.; Bie, N. N.; Song, X. L.; Yang, X. Q.; Yong, T. Y.; Zhao, Y. B.; Yang, X. L.; Gan, L. A Biomimetic Gold Nanocages-Based Nanoplatform for Efficient Tumor Ablation and Reduced Inflammation. Theranostics 2018, 19, Ochyl, L. J.; Bazzill, J. D.; Park, C.; Xu, Y.; Kuai, R.; Moon, J. J. PEGylated Tumor Cell Membrane Vesicles as a New Vaccine Platform for T Cancer Immunotherapy. Biomaterials 2018, 182,